The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 10 of 10
INCIPIT technology allowed the implementation of a multifunctional, micro-structured and electroconductive therapeutic product to treat patients with myocardial infarction, the leading cause of death for cardiovascular disease. Current therapies (drugs, bypass, angioplasty) do not restore the functionality of damaged myocardial tissue.
The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.
We propose a compact innovative spectroscopy system operating in the UV range. In the actual version, designed for gas, it exhibits: an aluminium tubular optical chamber (length can be adjusted; currently is 20 cm); a cheap commercial UV LED; a SiC visible blind UV detector designed and manufactured at the CNR-IMM facilities. The team developed also the electronic chain for wireless remote real time read out; while able to deal with pA current levels, it uses very cheap components and construction technology.
An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.
Design and testing of neoproteins with optimized nutritional value, according to needs, avoiding their degradation - thus maintaining a high production yield - and aggregation (which could make them indigestible). Neoproteins are produced and characterized in plant systems as bioreactors. We have already created zeolin, formed by the fusion of a bean seed protein with a portion of a maize seed protein.
Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:
The platform allows the deployment of a sensor network with peripheral nodes spread on the crop fields or on the environment for the monitoring of crop parameters/environmental parameters. The network architecture integrated LoRa peripheral nodes for short-medium range communication and star-center NB-IoT based for long range communication. It includes a web server and MySQL database for data storage and visualization. The network architecture is scalable to adapt to the area to monitor.
We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.
Our treatment demonstrated the ability to kill metastatic human melanoma cells, for which there are very few effective therapeutic approaches. Use of a specific Essential Oil (EO) to inhibit the replication of human metastatic melanoma cells. This EO can be used both for direct application to the skin, and administered by mouth to reach both primary and metastatic melanomas.